Chronic obstructive pulmonary disease: The golden decade. Implications for the diagnosis, prevention and treatment of chronic obstructive pulmonary disease

Miravitlles, 2009, Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities, Thorax, 64, 863, 10.1136/thx.2009.115725 Lopez, 1998, The global burden of disease, 1990–2020, Nat Med, 4, 1241, 10.1038/3218 Mannino, 2007, Global burden of COPD: risk factors, prevalence, and future trends, Lancet, 370, 765, 10.1016/S0140-6736(07)61380-4 Murray, 2013, Measuring the global burden of disease, N Engl J Med, 369, 448, 10.1056/NEJMra1201534 Agusti, 2010, Characterisation of COPD heterogeneity in the ECLIPSE cohort, Respir Res, 11, 122, 10.1186/1465-9921-11-122 Vestbo, 2013, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary, Am J Respir Crit Care Med, 187, 347, 10.1164/rccm.201204-0596PP Rodriguez-Roisin, 2012, The GOLD initiative 2011: a change of paradigm, Arch Bronconeumol, 48, 286, 10.1016/j.arbres.2012.02.018 Fletcher, 1977, The natural history of chronic airflow obstruction, Br Med J, 1, 1645, 10.1136/bmj.1.6077.1645 Rennard, 2008, Natural histories of chronic obstructive pulmonary disease, Proc Am Thorac Soc, 5, 878, 10.1513/pats.200804-035QC Vestbo, 2011, Changes in forced expiratory volume in 1 second over time in COPD, N Engl J Med, 365, 1184, 10.1056/NEJMoa1105482 Salvi, 2009, Chronic obstructive pulmonary disease in non-smokers, Lancet, 374, 733, 10.1016/S0140-6736(09)61303-9 Rodriguez-Roisin, 2000, Toward a consensus definition for COPD exacerbations, Chest, 117, 398S, 10.1378/chest.117.5_suppl_2.398S Tashkin, 2010, Frequent exacerbations of chronic obstructive pulmonary disease—a distinct phenotype, N Engl J Med, 363, 1183, 10.1056/NEJMe1008184 Hurst, 2010, Susceptibility to exacerbation in chronic obstructive pulmonary disease, N Engl J Med, 363, 1128, 10.1056/NEJMoa0909883 Barnes, 2009, Systemic manifestations and comorbidities of COPD, Eur Respir J, 33, 1165, 10.1183/09031936.00128008 Müllerova, 2013, Cardiovascular comorbidity in COPD: systematic literature review, Chest, 144, 1163, 10.1378/chest.12-2847 Solanes, 2012, Características de la enfermedad pulmonar obstructiva crónica en fase estable relacionadas con la inflamación sistémica, Med Clin (Barc), 139, 430, 10.1016/j.medcli.2012.03.033 Agustí, 2012, Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype, PLoS ONE, 7, e37483, 10.1371/journal.pone.0037483 Agusti, 2007, Systemic effects of chronic obstructive pulmonary disease: what we know and what we don’t know (but should), Proc Am Thorac Soc, 4, 522, 10.1513/pats.200701-004FM Hvidsten, 2010, Prevalence and predictors of undiagnosed chronic obstructive pulmonary disease in a Norwegian adult general population, Clin Respir J, 4, 13, 10.1111/j.1752-699X.2009.00137.x Buist, 2007, International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study, Lancet, 370, 741, 10.1016/S0140-6736(07)61377-4 Mannino, 2002, Chronic obstructive pulmonary disease surveillance—United States, 1971–2000, MMWR Surveill Summ, 51, 1 Raad, 2011, Effects of water-pipe smoking on lung function: a systematic review and meta-analysis, Chest, 139, 764, 10.1378/chest.10-0991 Tan, 1808, Marijuana and chronic obstructive lung disease: a population-based study, Can Med Assoc J, 2009, 14 Demeo, 2004, Familial aggregation of FEF25-75 and FEF25-75/FVC in families with severe, early onset COPD, Thorax, 59, 396, 10.1136/thx.2003.012856 2013 Rabe, 2007, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary, Am J Respir Crit Care Med, 176, 532, 10.1164/rccm.200703-456SO Agusti, 2013, FAQs about the GOLD 2011 assessment proposal of COPD: A comparative analysis of four different cohorts, Eur Respir J, 42, 1391, 10.1183/09031936.00036513 Anthonisen, 2005, The effects of a smoking cessation intervention on 14.5-year mortality: A randomized clinical trial, Ann Intern Med, 142, 233, 10.7326/0003-4819-142-4-200502150-00005 Nici, 2006, American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation, Am J Respir Crit Care Med, 173, 1390, 10.1164/rccm.200508-1211ST Ries, 2007, Pulmonary rehabilitation: Joint ACCP/AACVPR evidence-based clinical practice guidelines, Chest, 131, 4S, 10.1378/chest.06-2418 Appleton, 2006, Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease, Cochrane Database Syst Rev, 3, CD001104 Barr, 2005, Inhaled tiotropium for stable chronic obstructive pulmonary disease, Cochrane Database Syst Rev, 2, CD002876 Tashkin, 2009, Formoterol and tiotropium compared with tiotropium alone for treatment of COPD, COPD, 6, 17, 10.1080/15412550902724073 Van Noord, 2005, Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD, Eur Respir J, 26, 214, 10.1183/09031936.05.00140404 Calverley, 2003, Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial, Lancet, 361, 449, 10.1016/S0140-6736(03)12459-2 Wedzicha, 2008, The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide, Am J Respir Crit Care Med, 177, 19, 10.1164/rccm.200707-973OC Calverley, 2009, Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials, Lancet, 374, 685, 10.1016/S0140-6736(09)61255-1 Fabbri, 2009, Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials, Lancet, 374, 695, 10.1016/S0140-6736(09)61252-6 Welte, 2009, Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 180, 741, 10.1164/rccm.200904-0492OC Stoller, 2010, Oxygen therapy for patients with COPD: current evidence and the long-term oxygen treatment trial, Chest, 138, 179, 10.1378/chest.09-2555 McEvoy, 2009, Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial, Thorax, 64, 561, 10.1136/thx.2008.108274 Marin, 2010, Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome, Am J Respir Crit Care Med, 182, 325, 10.1164/rccm.200912-1869OC Naunheim, 2006, Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group, Ann Thorac Surg, 82, 431, 10.1016/j.athoracsur.2006.05.069 Orens, 2006, International guidelines for the selection of lung transplant candidates: 2006 update—A consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant, 25, 745, 10.1016/j.healun.2006.03.011 Sin, 2006, Mortality in COPD: role of comorbidities, Eur Respir J, 28, 1245, 10.1183/09031936.00133805 Fabbri, 2008, Complex chronic comorbidities of COPD, Eur Respir J, 31, 204, 10.1183/09031936.00114307 Anthonisen, 2002, Hospitalizations and mortality in the Lung Health Study, Am J Respir Crit Care Med, 166, 333, 10.1164/rccm.2110093